上海海怡莱涉嫌商业贿赂被罚30万元

Core Viewpoint - The National Medical Insurance Administration has announced a commercial bribery case involving a doctor from a women's and children's hospital in Shanghai, who received a benefit fee of 35,000 yuan for prescribing a drug, leading to a fine of 300,000 yuan for the involved company, Shanghai Haiyilai Enterprise Consulting Management Partnership [1][2] Group 1 - The involved company, Haiyilai, signed a one-year information service agreement with Hongjian Pharmaceutical Co., Ltd. to promote the drug "Dahansuan Sodium Injection" (brand name: Wanmai Ning) in Shanghai [1] - Haiyilai promised to maintain and increase the total sales of Wanmai Ning in Shanghai in exchange for the marketing service contract [1] - The sales promotion director and shareholder of Haiyilai promised the doctor a benefit fee for prescribing the drug, resulting in a total of 18,275 units prescribed during the year [1] Group 2 - The total income from market promotion and information services for Wanmai Ning in 2023 was 868,677 yuan [1] - The market supervision authority determined that Haiyilai's actions constituted commercial bribery, violating the Anti-Unfair Competition Law of the People's Republic of China [2] - An administrative penalty of 300,000 yuan was imposed on Haiyilai for its actions [2]